Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30712252 | 0.93 | CHRM1 (0.38) | CHRM1HRH3 | |
| SCHEMBL14978771 | 0.81 | HRH3 (0.39) | CHRM1HRH3MMP1MMP9MMP13 | |
| SCHEMBL14964734 | 0.81 | CHRM1 (0.53) | CHRM1HRH3MMP1MMP9MMP13 | |
| SCHEMBL16210465 | 0.79 | CHRM1 (0.55) | CHRM1HRH3 | |
| SCHEMBL14978786 | 0.78 | CHRM1 (0.70) | CHRM1L3MBTL1 | |
| SCHEMBL15623191 | 0.73 | CHRM1 (0.48) | CHRM1 | |
| SCHEMBL18922668 | 0.73 | CHRM1 (0.48) | CHRM1 | |
| SCHEMBL14978785 | 0.73 | CHRM1 (0.56) | CHRM1MMP13 | |
| SCHEMBL3349215 | 0.73 | CHRM1 (0.38) | CHRM1HRH3PLATL3MBTL3L3MBTL1 | |
| SCHEMBL17692977 | 0.72 | HRH3 (0.39) | HRH3L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11793817-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| US-10413553-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | NXERA PHARMA UK LIMITED (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2780015-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072705-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072705-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885HRH3 85/4885MMP1 3258/4885 |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885HRH3 85/4885MMP1 3258/4885 |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885HRH3 85/4885MMP1 3258/4885 |
| US-20210353637-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885HRH3 85/4885MMP1 3258/4885 |
| US-10973832-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885HRH3 85/4885MMP1 3258/4885 |
| US-10413553-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885HRH3 85/4885MMP1 3258/4885 |
| US-11793817-B2 | Muscarinic M1 receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM1 1/4885HRH3 85/4885MMP1 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.